Chris Kotanidis
@cpkotanidis.bsky.social
Editorial Fellow at New England Journal of Medicine | PostDoc at Harvard Med | DPhil University of Oxford | MD Aristoteleio
#GLP1s have transformed #obesity care, but can they compete with surgery? #AMichaelLincoff & #ScottShikora argue the pros and cons of #semaglutide vs #bariatricsurgery for a man with obesity in our @nejm.org Clinical Decisions www.nejm.org/doi/full/10....
Managing Obesity | NEJM
This feature about a man with obesity offers a case vignette accompanied by two essays,
one supporting initiation of semaglutide therapy and the other recommending bariatric
and metabolic surgery.
www.nejm.org
September 10, 2025 at 8:35 AM
#GLP1s have transformed #obesity care, but can they compete with surgery? #AMichaelLincoff & #ScottShikora argue the pros and cons of #semaglutide vs #bariatricsurgery for a man with obesity in our @nejm.org Clinical Decisions www.nejm.org/doi/full/10....
Reposted by Chris Kotanidis
Congratulations to Dr Christos Kotanidis who has been awarded the 2025 ESC Young Investigator Award in Preventative Cardiology at the European Society of Cardiology Congress in Madrid.
Read more 👇
shorturl.at/KU2Be
Read more 👇
shorturl.at/KU2Be
Christos Kotanidis wins ESC Young Investigator Award 2025 in Preventive Cardiology
Congratulations to Dr Christos Kotanidis, NIHR-funded Academic Clinical Lecturer in Cardiology, who has been awarded the 2025 ESC Young Investigator Award in Preventive Cardiology at the European Soci...
shorturl.at
September 8, 2025 at 12:42 PM
Congratulations to Dr Christos Kotanidis who has been awarded the 2025 ESC Young Investigator Award in Preventative Cardiology at the European Society of Cardiology Congress in Madrid.
Read more 👇
shorturl.at/KU2Be
Read more 👇
shorturl.at/KU2Be
Reposted by Chris Kotanidis
#ZakKohane on #AI in #PeerReview: the surge in scientific publication is straining the conventional review system beyond capacity. @ai.nejm.org piloting AI-augmented fast track review: manuscripts w high prior of being good gets assigned to #GPT5 + a human, disposition reviewed by editorial team!
September 5, 2025 at 1:27 PM
#ZakKohane on #AI in #PeerReview: the surge in scientific publication is straining the conventional review system beyond capacity. @ai.nejm.org piloting AI-augmented fast track review: manuscripts w high prior of being good gets assigned to #GPT5 + a human, disposition reviewed by editorial team!
Reposted by Chris Kotanidis
Comparing submitted vs published RCT abstracts eval'd at @nejm.org in 4 domains (design, outcome, AEs, conclusions). published abstracts improved in a mean 0.9 domains. More improvements observed in leading gen med vs 433 other journals (72 % vs 48%) www.acpjournals.org/...
@cpkotanidis.bsky.social
@cpkotanidis.bsky.social
September 4, 2025 at 6:30 PM
Comparing submitted vs published RCT abstracts eval'd at @nejm.org in 4 domains (design, outcome, AEs, conclusions). published abstracts improved in a mean 0.9 domains. More improvements observed in leading gen med vs 433 other journals (72 % vs 48%) www.acpjournals.org/...
@cpkotanidis.bsky.social
@cpkotanidis.bsky.social
Reposted by Chris Kotanidis
Well done @cpkotanidis.bsky.social ! Also check out our manuscript in @annalsofim.bsky.social url.us.m.mimecastprotect.com/s/kNYpCDkAO2...
September 4, 2025 at 7:07 PM
Well done @cpkotanidis.bsky.social ! Also check out our manuscript in @annalsofim.bsky.social url.us.m.mimecastprotect.com/s/kNYpCDkAO2...
Excited to present our work tomorrow on a novel #AI #metabolomics score to predict #cardiovascular risk in #psoriasis at the #ESCCongress #WCCardio 2025 Young Investigator Award session in Preventive Cardiology. #PreventiveCardiology #CardioRheumatology #YIA
August 29, 2025 at 6:48 PM
Excited to present our work tomorrow on a novel #AI #metabolomics score to predict #cardiovascular risk in #psoriasis at the #ESCCongress #WCCardio 2025 Young Investigator Award session in Preventive Cardiology. #PreventiveCardiology #CardioRheumatology #YIA
Reposted by Chris Kotanidis
Four Original Articles were simultaneously published in NEJM and presented earlier today at this year’s #ESCCongress in Spain.
@escardio.bsky.social
@escardio.bsky.social
August 29, 2025 at 1:01 PM
Four Original Articles were simultaneously published in NEJM and presented earlier today at this year’s #ESCCongress in Spain.
@escardio.bsky.social
@escardio.bsky.social
Reposted by Chris Kotanidis
The #1 cause of death in women is heart disease. A new report makes the case for treating women with statins who have a high inflammation marker (hs-CRP) but no traditional risk factors academic.oup.com/eurheartj/ad...
August 29, 2025 at 2:49 PM
The #1 cause of death in women is heart disease. A new report makes the case for treating women with statins who have a high inflammation marker (hs-CRP) but no traditional risk factors academic.oup.com/eurheartj/ad...
Reposted by Chris Kotanidis
🎥 Snackable Science from #ESCCongress 2025 in Madrid!
Roxana Mehran & Michael Gibson break down the new Focus Update of the 2019 #ESCGuidelines on #dyslipidaemias with the latest recommendations you need to know 👇
Roxana Mehran & Michael Gibson break down the new Focus Update of the 2019 #ESCGuidelines on #dyslipidaemias with the latest recommendations you need to know 👇
August 29, 2025 at 1:16 PM
🎥 Snackable Science from #ESCCongress 2025 in Madrid!
Roxana Mehran & Michael Gibson break down the new Focus Update of the 2019 #ESCGuidelines on #dyslipidaemias with the latest recommendations you need to know 👇
Roxana Mehran & Michael Gibson break down the new Focus Update of the 2019 #ESCGuidelines on #dyslipidaemias with the latest recommendations you need to know 👇
Reposted by Chris Kotanidis
For a man with #obesity, would you recommend the initiation of semaglutide therapy or bariatric and metabolic surgery? Read the case vignette and essays on both treatment options and cast your vote: nej.md/3HiAnJz
#MedSky #EndoSky
#MedSky #EndoSky
August 15, 2025 at 4:08 PM
For a man with #obesity, would you recommend the initiation of semaglutide therapy or bariatric and metabolic surgery? Read the case vignette and essays on both treatment options and cast your vote: nej.md/3HiAnJz
#MedSky #EndoSky
#MedSky #EndoSky
The win ratio method is gaining traction in #RCTs. Is it just a trend or a smarter way to look at composite hierarchical outcomes? We break it down in our latest Stats, STAT!📊 in NEJM Evidence. youtube.com/watch?v=jKtF... #stats @nejm.org @sarahgorey.bsky.social @chardin.bsky.social @ai.nejm.org
How Win Ratios Work | NEJM Evidence
YouTube video by NEJM Group
youtube.com
July 31, 2025 at 11:41 AM
The win ratio method is gaining traction in #RCTs. Is it just a trend or a smarter way to look at composite hierarchical outcomes? We break it down in our latest Stats, STAT!📊 in NEJM Evidence. youtube.com/watch?v=jKtF... #stats @nejm.org @sarahgorey.bsky.social @chardin.bsky.social @ai.nejm.org
Reposted by Chris Kotanidis
1/ 🚨 NEW #BeyondJournalClub w/ @nejm.org: REDUCE-AMI
What is the long term benefit of beta blockers in patients with preserved EF following an MI?
🖥️: www.coreimpodcast.com/2025/06/25/b...
What is the long term benefit of beta blockers in patients with preserved EF following an MI?
🖥️: www.coreimpodcast.com/2025/06/25/b...
June 25, 2025 at 11:55 AM
1/ 🚨 NEW #BeyondJournalClub w/ @nejm.org: REDUCE-AMI
What is the long term benefit of beta blockers in patients with preserved EF following an MI?
🖥️: www.coreimpodcast.com/2025/06/25/b...
What is the long term benefit of beta blockers in patients with preserved EF following an MI?
🖥️: www.coreimpodcast.com/2025/06/25/b...
Reposted by Chris Kotanidis
In older patients with acute coronary syndrome, an early invasive strategy did not reduce all-cause mortality but decreased recurrent myocardial infarction and repeated revascularization. https://ja.ma/40hDK9G
June 24, 2025 at 12:00 PM
In older patients with acute coronary syndrome, an early invasive strategy did not reduce all-cause mortality but decreased recurrent myocardial infarction and repeated revascularization. https://ja.ma/40hDK9G
Reposted by Chris Kotanidis
What is it like to be an NEJM editorial fellow for a year? This year’s fellows discuss what they have learned, how their experience will help their career, and what surprised them. Apply for the 2026–27 NEJM editorial fellowship by August 1. Learn more: nej.md/3cCQajB
#MedSky #MedEd
#MedSky #MedEd
June 13, 2025 at 6:48 PM
What is it like to be an NEJM editorial fellow for a year? This year’s fellows discuss what they have learned, how their experience will help their career, and what surprised them. Apply for the 2026–27 NEJM editorial fellowship by August 1. Learn more: nej.md/3cCQajB
#MedSky #MedEd
#MedSky #MedEd
Reposted by Chris Kotanidis
60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Read the full trial results: nej.md/4hRGaTY
#MedSky #CardioSky @cpkotanidis.bsky.social
#MedSky #CardioSky @cpkotanidis.bsky.social
June 14, 2025 at 4:04 PM
60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Read the full trial results: nej.md/4hRGaTY
#MedSky #CardioSky @cpkotanidis.bsky.social
#MedSky #CardioSky @cpkotanidis.bsky.social
Reposted by Chris Kotanidis
A 73-year-old woman presented with severe chest pain. She had undergone multivessel percutaneous coronary intervention 2.5 years earlier. Angiography revealed a large thrombus in an LAD artery stent (shown in videos). Read the full case details: nej.md/4jC2aSa
#MedSky #CardioSky
#MedSky #CardioSky
June 9, 2025 at 1:09 PM
A 73-year-old woman presented with severe chest pain. She had undergone multivessel percutaneous coronary intervention 2.5 years earlier. Angiography revealed a large thrombus in an LAD artery stent (shown in videos). Read the full case details: nej.md/4jC2aSa
#MedSky #CardioSky
#MedSky #CardioSky
Reposted by Chris Kotanidis
Really enjoying @cpkotanidis.bsky.social’s fascinating presentation on his interesting work at @brighamandwomens.bsky.social on identifying risk markers of CVD in patients with IMIDs 🤩👏👏👏
May 6, 2025 at 8:30 PM
Really enjoying @cpkotanidis.bsky.social’s fascinating presentation on his interesting work at @brighamandwomens.bsky.social on identifying risk markers of CVD in patients with IMIDs 🤩👏👏👏
New research alert: Our latest report highlights a significant reduction in coronary #inflammation and residual inflammatory risk as captured by #CCTA imaging using CaRi-Heart AI in women with #BreastCancer 2 years post-RT
#AI #CardioOncology #CardioEd #EHJ
@escardio.bsky.social
#AI #CardioOncology #CardioEd #EHJ
@escardio.bsky.social
Coronary inflammation and cardiovascular risk in breast cancer after radiotherapy
Radiotherapy (RT) is known to reduce the rate of disease recurrence following breast-conserving surgery in patients with breast cancer, but also entails ir
academic.oup.com
April 22, 2025 at 1:57 PM
New research alert: Our latest report highlights a significant reduction in coronary #inflammation and residual inflammatory risk as captured by #CCTA imaging using CaRi-Heart AI in women with #BreastCancer 2 years post-RT
#AI #CardioOncology #CardioEd #EHJ
@escardio.bsky.social
#AI #CardioOncology #CardioEd #EHJ
@escardio.bsky.social
Reposted by Chris Kotanidis
Presented at #ACC25:
In the PROTECT-TAVI trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner). Full trial results: nej.md/41RONXi
@accintouch.bsky.social
In the PROTECT-TAVI trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner). Full trial results: nej.md/41RONXi
@accintouch.bsky.social
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation | NEJM
Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence t...
nej.md
March 30, 2025 at 3:11 PM
Presented at #ACC25:
In the PROTECT-TAVI trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner). Full trial results: nej.md/41RONXi
@accintouch.bsky.social
In the PROTECT-TAVI trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner). Full trial results: nej.md/41RONXi
@accintouch.bsky.social
Ever wondered how interim analyses work in #RCTs? 📊 Check out our Stats, STAT! video at NEJM Evidence: @nejm.org @ai.nejm.org @sarahgorey.bsky.social evidence.nejm.org/doi/full/10.... #MedStats #ClinicalTrials
How Interim Analyses Work
This Stats, STAT! animated video explores interim analyses in clinical trials. During
these evaluations of the data, researchers may assess safety, efficacy, and verify
sample size assumptions, but...
evidence.nejm.org
March 26, 2025 at 2:09 PM
Ever wondered how interim analyses work in #RCTs? 📊 Check out our Stats, STAT! video at NEJM Evidence: @nejm.org @ai.nejm.org @sarahgorey.bsky.social evidence.nejm.org/doi/full/10.... #MedStats #ClinicalTrials
Reposted by Chris Kotanidis
Tirzepatide was previously shown to provide sustained weight reductions in adults with #obesity. Longer-term findings in adults with both obesity and prediabetes are summarized in a new Quick Take video. youtu.be/c9uazgSdDJc
#MedSky #EndoSky
#MedSky #EndoSky
- YouTube
Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
youtu.be
March 8, 2025 at 8:58 PM
Tirzepatide was previously shown to provide sustained weight reductions in adults with #obesity. Longer-term findings in adults with both obesity and prediabetes are summarized in a new Quick Take video. youtu.be/c9uazgSdDJc
#MedSky #EndoSky
#MedSky #EndoSky
🫀New research🫀 Across 6 #RCTs (n=2,257) early invasive management in #female patients with #NSTEACS did not reduce all-cause mortality or MI risk at 6 months vs. delayed management. #AHAJournals @drroxmehran.bsky.social @vijaykunadian.bsky.social
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
Early Versus Delayed Invasive Management of Female Patients With Non–ST-Elevation Acute Coronary Syndrome: An Individual Patient Data Meta-Analysis | Circulation: Cardiovascular Interventions
BACKGROUND: Female patients are at greater risk of adverse events following non–ST-elevation acute
coronary syndrome but less frequently receive guideline-recommended coronary angiography
and revascul...
www.ahajournals.org
March 7, 2025 at 4:50 PM
🫀New research🫀 Across 6 #RCTs (n=2,257) early invasive management in #female patients with #NSTEACS did not reduce all-cause mortality or MI risk at 6 months vs. delayed management. #AHAJournals @drroxmehran.bsky.social @vijaykunadian.bsky.social
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
Reposted by Chris Kotanidis
In the HELIOS-B trial, researchers assessed the efficacy and safety of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. NEJM Editorial Fellow Christos Kotanidis, MD, DPhil, summarizes the results. Full trial: nej.md/3X5nl5Q
#MedSky #CardioSky @cpkotanidis.bsky.social
#MedSky #CardioSky @cpkotanidis.bsky.social
March 5, 2025 at 5:59 PM
In the HELIOS-B trial, researchers assessed the efficacy and safety of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. NEJM Editorial Fellow Christos Kotanidis, MD, DPhil, summarizes the results. Full trial: nej.md/3X5nl5Q
#MedSky #CardioSky @cpkotanidis.bsky.social
#MedSky #CardioSky @cpkotanidis.bsky.social
Reposted by Chris Kotanidis
In a new editorial, NEJM Editor-in-Chief Eric J. Rubin, MD, PhD, comments on the effects of the raft of executive orders from the current administration on scientific research and public health. Read the full editorial: nej.md/4gXeRFW
#MedSky
#MedSky
March 3, 2025 at 5:05 PM
In a new editorial, NEJM Editor-in-Chief Eric J. Rubin, MD, PhD, comments on the effects of the raft of executive orders from the current administration on scientific research and public health. Read the full editorial: nej.md/4gXeRFW
#MedSky
#MedSky